Nasdaq
$0.9400▲ 1.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $119.6MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 4d agoPre-market26.10.21 20:006-KKey event#●●●#●●●
Tiziana Life Sciences Ltd
Tiziana Life Sciences announced that its management and business development team will attend the 10th Joint ACTRIMS-ECTRIMS meeting in Toronto, Canada, from October 21 to 23, 2026. The company will use this forum to discuss the clinical progress of its lead candidate, intranasal foralumab, and explore potential scientific and business collaborations.…more
$0.9400+1.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:306-KKey event
Tiziana Life Sciences Ltd
Tiziana Life Sciences reported a net loss of $12.4 million for the first half of 2026. The company provided updates on the clinical progress of its lead candidate, foralumab, and reported cash and cash equivalents of $3.2 million as of June 30, 2026.…more
$0.9400+1.06%vs prev closeView filingShare - 10.16Pre-market26.10.16 20:006-KKey event
Tiziana Life Sciences Ltd
Tiziana Life Sciences has completed dosing for the last patient in its Phase 2 clinical trial evaluating intranasal foralumab for early/mild Alzheimer's disease. The study assesses the safety and efficacy of foralumab as a monotherapy and in combination with FDA-approved treatments, with topline data expected in Q1 2027.…more
$0.9400+1.06%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16Pre-market26.10.16 20:00#●●●#●●●
Tiziana Completes Patient Dosing in Phase 2 Alzheimer’s Trial
Tiziana Life Sciences has completed patient dosing for its Phase 2 clinical trial of intranasal foralumab in patients with early-stage Alzheimer’s disease. Topline data is expected in the first quarter of 2027, though the clinical stage remains early.…more
$0.9400+1.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:05
●●●●●●●● ●●●●● ●●●●●●
Tiziana Life Sciences has submitted a request for FDA orphan drug designation for its drug candidate, foralumab, to treat multiple system atrophy. While this marks a step in the drug development process, the impact remains neutral until further regulatory progress is made.…more
$0.9400+1.06%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 20:00
●●●●●●●● ●●●●● ●●●●●●
Tiziana Life Sciences has begun dosing the first participants in its Phase 2a BANYAN clinical trial for intranasal foralumab in patients with ALS. This study aims to evaluate the safety and biological impact of the treatment in early-stage patients.…more
$0.9400+1.06%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report